211 results about "Cyclobutane" patented technology

The radiolabeled non-natural amino acid 1-amino-3-cyclobutane-1-carboxylic acid (ACBC) and its analogs are candidate tumor imaging agents useful for positron emission tomography and single photon emission computed tomography due to their selective affinity for tumor cells. The present invention provides methods for stereo-selective synthesis of syn-ACBC analogs. The disclosed synthetic strategy is reliable and efficient and can be used to synthesize a gram quantity of various syn-isomers of the ACBC analogs, particularly, syn-[¹⁸F]-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC) and syn-[¹²³I]-1-amino-3-iodocyclobutane-1-carboxylic (IACBC) acid analogs.

A polymer for ion conductor applications includes a polymer segment having a perfluorocyclobutyl moiety and a polymer segment not having such a moiety. One of these polymer segments is sulfonated to improve ionic conductivity. Fuel cells incorporating the ion conducting polymers are provided.

The invention provides a liquid crystal alignment agent for photo alignment, a liquid crystal alignment layer for photo alignment, and a liquid crystal display element. The liquid crystal alignment agent provided by the invention has a polyamide acid or a derivative thereof, the polyamide acid or the derivative thereof may be formed by reacting a mixer of cyclobutane tetracarboxylic dianhydride or tetracarboxylic dianhydride with specific aromatic diamine of an alkyl chain of a molecule with a carbon number larger than 4. With the adoption of the liquid crystal alignment agent, a liquid crystal alignment layer good in sensitivity of chemical change caused by light irradiation, excellent in alignment property of liquid molecule and high in optical transmittivity is formed. In addition, by applying the photo alignment layer to the liquid crystal display element, the liquid crystal display element with excellent display characteristics can be obtained.

The invention disclosed an aryl nitrile group thiazole derivative for inhibiting the activity of xanthine oxidase, a method for preparing the same and application thereof. In the aryl nitrile group thiazole, R1 is methyl, ethyl, propyl, isopropyl, isobutyl, methyl cyclopropane, methyl cyclobutane, isoamyl, methyl cyclopentane, methyl cyclohexane or aromatic ring methyl, R2 is methyl or trifluoromethyl, and R3 is formic acid, sodium formate, potassium formate, lithium formate, methyl formate, or ethyl formate. Simultaneously, the invention discloses a method for synthesizing the aryl nitrile group thiazole derivative by using inexpensive raw materials, which has the advantages of simple operation, high yield, easy purification of products, application to industrial production and the like, and can obtain an efficient compound with low toxicity through screening; besides, the effective compound is expected to be widely applied to inhibit the activity of the xanthine oxidase required on animals and humans, and to become a new generation of antigout drugs and hyperuricemia drugs with special effect.

The invention provides a novel preparation method of Apalutamide. According to the novel preparation method, 2-fluoro-4-bromo-N-methyl benzene methanamine amide, 1-amino cyclobutyl carboxylate hydrochloride, and the like are taken as initial raw materials, and substitution reaction is carried out so as to obtain 1-((3-fluoro-4-(methyl carbamyl)phenyl)amino) cyclobutane-1-carboxylic acid, wherein synthesis yield is higher than 70%, and purity is higher than 97.2%; then esterification is carried out so as to obtain 1-((3-fluoro-4-(methyl carbamyl)phenyl)amino) cyclobutane-1-carboxylic ester, wherein synthesis yield is higher than 83%, and purity is higher than 97.8%; and at last, ring closing reaction with 2-cyan-3-trifluoromethyl-5-isothiocyano pyridine is carried out so as to obtain Apalutamide, wherein yield is higher than 68%, and purity is higher than 98.1%. The preparation method possesses following advantages: the raw materials are easily available; technology is simple; operationis convenient; yield is high; and cost is low.

The object of the present invention is to provide an organosilicon compound having an oxetanyl group, which has a high proportion of an inorganic part in the structure, which, after production thereof, is stable with no gelling, and which has excellent storage stability when it is formed into a composition, and a production method thereof and a curable composition. The organosilicon compound is a compound having an oxetanyl group obtained by a method including a process in which a silicon compound A represented by the formula (1) and a silicon compound B having four siloxane bond-forming groups are subjected to hydrolysis and condensation at a ratio of 0.3 to 2.8 mol of silicon compound B based on 1 mol of silicon compound A.

[In the formula, R⁰ is an organic group having an oxetanyl group, R¹ is an alkyl group having 1 to 6 carbon atoms, an aralkyl group having 7 to 10 carbon atoms, an aryl group having 6 to 10 carbon atoms, or an organic group having an oxetanyl group, X is a hydrolyzable group, and n is 0 or 1.]

The invention discloses a water-soluble carboxyl-bridge dicaryon Pt (II) anti-tumor complex, which has a chemical name of cis-tetrammine-miu-di (3-acetoxy-1, 1-cyclobutane dicarboxylate-O1, O2) dicaryon platinum (II), and can be synthesized by adopting the method preparing the conventional platinum based anti-cancer drug. The anticancer activity of the complex of the invention is higher than the platinum based drug of carboplatin commonly used in clinic, the toxic side effect of the invention is significantly lower than the toxic side effect of carboplatin, and the invention can be made into lyophilized powder or injecta to be used in the clinical cancer treatment.

A photoalignment agent includes: a copolymer obtained from at least one of cyclobutane dianhydride (CBDA) and a cyclobutane dianhydride derivative, and a diamine; and a cross-linking agent including an alkylene group —C_nH_2n—, n being a natural number.

A medicine of Pululishaxing is prepared by: using 4-bromomethyl-5-methyl 1,3-dioxacycloene pentadione as start material, addition reacting with piperazine to produce 5-methyl-4-piperazinemethyl-1,3-dioxacycloenepentenedione, finally, reacting with 6,7- difluoro -1- methyl - 4 -oxo-4-[1,3]thioaza cyclobutane [3,2 -a] quinoline-3- carboxylic acid. The process is simple, high purity, high yield. Their purity of crude product can reach 97.5% more. Yield of the product is more than 58%, increased 45% compared with prior art. It is proficial.

Provided is a monomer composition that has rapid curability and can be cured rapidly, even in the presence of oxygen and/or water, to form a cured product having excellent adhesion to a wide variety of substrates. The monomer composition according to the present invention contains a vinyl ether compound (A). The vinyl ether compound (A) includes a vinyl ether compound (a) having a cyclic ether skeleton. The monomer composition further contains at least one compound selected from the group consisting of a vinyl ether compound (a′) having a chain hydrocarbon skeleton, a divinyl ether compound (a″-1) having a cyclic hydrocarbon skeleton, an oxetane compound (B), and an epoxy compound (C).

The invention relates to new type precursor compounds for preparing platinum carrying catalyst [Pt(NH3)4]X2(X2=oxalate, malonate and 1, 1-cyclobutanes dicarboxylate), and a method for making same. The compounds can provide complex cation [Pt(NH3)4]<2+>, is propitious to perform high-performance catalyst on carrier or sodium-typed molecular sieve for adsorbing and exchanging electrified negativity. The preparation of the compounds uses K2PtCl4 as starting material to obtain the intermediate body cis-[Pt(NH3)2I2] by iodination and ammine substitution, and then to obtain the target compounds after hydration, coordination and ammine displacement, and the yield can reach 90.

The invention discloses a method for synthesizing dicycloplatin by microwave catalysis. The method comprises the steps: mixing carboplatin and 1,1-cyclobutane dicarboxylic acid in a corresponding ratio as well as a solvent; according to a molar ratio of the carboplatin to the 1,1-cyclobutane dicarboxylic acid of 1:(1 to 1.5), performing a reaction for 9 minutes in microwaves, controlling a temperature of 30 DEG C, then carrying out decompressing condensing at a temperature of 35 DEG C, washing a filter cake with ethyl alcohol, and after vacuum drying, obtaining the dicycloplatin. The method disclosed by the invention has the advantages of convenience for operation, mild reaction condition, short reaction time, high reproducibility ad high product purity.

The invention belongs to the field of organic synthesis and discloses a method for synthesizing trans-3-hydroxy cyclobutyl formic acid. The method comprises the following steps: by using an appropriate reducing agent, reducing 3-carbonyl-cyclobutane formate (C1-C6 alkyl ester) into single trans-3-hydroxy cyclobutyl formic ether in an efficient stereoselectivity manner, and further performing a Mitsunobu reaction and hydrolysis, thereby obtaining single trans-3-hydroxy cyclobutyl formic acid. The method provided by the invention is high in synthesis method raw material availability, mild in reaction condition, good in stereoselectivity and relatively high in yield; in addition, aftertreatment and purification are both easy to operate, and the method is applicable to industrial amplified production.

The invention relates to a novel water-soluble platinum (II) anticancer complex, a leaving group of which is 3-acetoxy-1 and 1-cyclobutane dicarboxylate root (3-COO-CBDCA), and a carrier of which is an ammonia/amine ligand of a listed platinum antitumor drug. The carrier comprises ammonia (NH3), 1R, 2R-diamino cyclohexane (DACH), 1,2-bis (aminomethyl)-cyclobutane, 2-isopropyl-(4R, 5R)-4, 5-bis (aminomethyl)-1 and 3-dioxo-cyclopentane. The novel water-soluble platinum (II) anticancer complex can be synthesized by the normal preparation method of the platinum antitumor drug. The antitumor activity of the complex is equivlent to that of the prior carboplatin frequently used in clinic, and the toxicity and side-effect of the complex are obviously less than those of carboplatin, can be made into freeze-dried powder or injection for cancer treatment in clinic.

The present invention relates to a new kind of water soluble anticancer Pt (II) compound, cis-[2-substitutent- (4Rú¼5R)-4ú¼5-bis(aminoethyl)-lú¼3-dioxycyclopentaneíñ3-hydroxy-1ú¼1-cyclobutane dicarboxylic radical- Pt (II)], with the substitutent being methyl, ethyl or isopropyl radical. One of the preparation process includes the reaction of material cis-[PtA2I2], with A2 being 2-substitutent- (4Rú¼5R)-4ú¼5-bis(aminoethyl)-lú¼3-dioxycyclopentane, and 3-hydroxy-1ú¼1- cyclobutane dicarboxyl-Ag, filtering to separate AgI, concentrating the mother liquid and freeze drying to obtain the coarse product. The other preparation process includes the first reaction of cis-[PtA2I2] and Ag2SO4, filtering to separate AgI, the reaction of the mother liquid and 3-hydroxyl-1ú¼1-cyclobutane dicarboxylic Ba, filtering to separate BaSO4, concentrating mother liquid, and freeze drying to obtain the coarse product. The coarse product is re-crystallized in water/alcohol system to obtain refined product. The compound of the present invention has anticancer activity and less toxic side effect, and may be clinical use for treating cancers.

Ulifloxacin has low water solubility and low bioavailability. The invention relates to an Ulifloxacin salt, a preparation thereof, a kit having the medicinal antibiotic preparation and the use of the new Ulifloxacin salt in the preparation of an anti-bacterial-infection medicine. The invention particularly relates to a new medicinal preparation which is used for injection and can be stored stablyand the chemical name of which is 6-fluoro-1-methy-7-(1-piperazinyl)-4-oxo-4H-[1,3]thiazeto[3,2-alpha]quinoline-3-carboxylate. In the invention, the medicinal preparation is administrated by direct injection in form of thiabutyldine quinoline carboxylate, the solubility is improved, the bioavailability is improved and treatment effect is enhanced.

The invention discloses a carbon dioxide based non-fluorine refrigerant, which is characterized in that THE carbon dioxide with mass percentage between 5 and 20 percent is mixed with one or more components as the propane, butane and cyclobutane, so as to produce environmental protection and green refrigerant. The invention has the advantages of no toxicity, no pollutions, no corrosions or less combustibleness.